Immutep (ASX:IMM) Net Change in Cash : A$40.21 Mil (TTM As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

What is Immutep Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Immutep's Net Change in Cash for the three months ended in Dec. 2023 was A$-6.41 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was A$40.21 Mil.

Immutep Net Change in Cash Historical Data

The historical data trend for Immutep's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Net Change in Cash Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Change in Cash

Get a 7-Day Free Trial

-6.91

9.76

34.27

19.40

43.42

Immutep Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															-13.18	68.22	-13.27	-6.41	-8.32

Immutep Net Change in Cash Calculation

Immutep's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-35.356	+	-0.083	+	76.022	+	2.839
	=	43.42

Immutep's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -5.595 + -0.081 + -0.072 + -0.66

= -6.41

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was A$40.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immutep Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Immutep's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (ASX:IMM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Net Change in Cash

Comparable Companies

ASX:IMU ASX:BOT ASX:PYC ASX:OPT ASX:CUV ASX:RAC ASX:DXB ASX:PIQ ASX:ALA ASX:RCE OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX

Traded in Other Exchanges

PRRUF:USA IMMP:USA YP1B:Germany

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (ASX:IMM) Headlines

No Headlines